EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study

Henar Calvo-Sánchez iD, Lorena Jara-Fernández iD, Raquel Encijo-Heredia iD, Irene Villarino iD, Rubén Alvarado iD, Marta Quiñones-Calvo iD, María-Luisa Gutiérrez iD, Joaquín Miquel iD, Miguel Torralba iD, Myriam Catalá iD, José Gómez iD, Sonia Albertos iD und 3 weitere

Liver International · 2026-08 · 46 (8)

DOI: 10.1111/liv.70798 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 24.07.2026. Verfasst von Henar Calvo-Sánchez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Service of Gastroenterology, University Hospital of Guadalajara, Guadalajara, Spain. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Agencia Estatal de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear. We evaluated whether CME was associated with lower HCC risk after SVR.

Methods

We analysed a multicentre cohort of 1531 patients who achieved SVR after direct‐acting antiviral therapy (median follow‐up, 75.5 months). Metformin exposure was modelled as a time‐updated cumulative variable in start–stop Cox models to control for immortal‐time bias. Stabilised inverse probability weighting addressed confounding by indication and censoring. The overall model was sex‐stratified and adjusted for FIB‐4, clinically significant portal hypertension (CSPH), type 2 diabetes mellitus (T2DM) and smoking. A prespecified T2DM‐restricted analysis used T2DM‐specific IPTW plus IPCW, sex stratification and CSPH adjustment.

Results

During follow‐up, 50 patients developed HCC. Crude incidence was highest among patients with FIB‐4 > 3.25, CSPH and T2DM without metformin exposure (4.84 cases per 100 person‐years). In the overall weighted model, CME was associated with lower HCC risk (HR, 0.46 per year; 95% CI, 0.27–0.77; p = 0.004). CSPH, T2DM, smoking and FIB‐4 > 3.25 independently increased risk. In the T2DM‐restricted model, each additional year remained associated with lower HCC hazard (HR, 0.49; 95% CI, 0.29–0.84; p = 0.009), whereas CSPH was associated with higher risk (HR, 6.04; 95% CI, 2.12–17.19; p < 0.001).

Conclusion

After SVR, CME was associated with lower HCC risk; this possible duration‐dependent inverse association was clinically interpretable only among metformin‐eligible patients with T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularHepatitis C, ChronicHypoglycemic AgentsLiver NeoplasmsMetforminAgedFemaleHumansMaleMiddle AgedDiabetes Mellitus, Type 2Hypertension, PortalIncidenceProportional Hazards ModelsRisk FactorsSustained Virologic Response

Stichwörter der Autor:innen

causal inferencehepatitis C treatmentinverse probability weightingportal hypertensionrisk stratificationtype 2 diabetes mellitus

Substanzen

Antiviral AgentsHypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Service of Gastroenterology, University Hospital of Guadalajara, Guadalajara, Spain.
  • Translational Research Group on Cellular Immunology (GITIC), Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Guadalajara, Spain.
  • Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Madrid, Spain.
  • Service of Gastroenterology, University Hospital Fundación Alcorcón, Madrid, Spain.
  • Service of Internal Medicine, University Hospital of Guadalajara, Guadalajara, Spain.
  • Department of Biology and Geology, Physics and Inorganic Chemistry, ESCET, Rey Juan Carlos University, Madrid, Spain.

ORCID-Profile: Henar Calvo-Sánchez, Lorena Jara-Fernández, Raquel Encijo-Heredia, Irene Villarino, Rubén Alvarado, Marta Quiñones-Calvo, María-Luisa Gutiérrez, Joaquín Miquel, Miguel Torralba, Myriam Catalá, José Gómez, Sonia Albertos, Óscar Barquero-Pérez, Conrado Fernández-Rodríguez, Juan-Ramón Larrubia

Förderung

  • Instituto de Salud Carlos III
  • Agencia Estatal de Investigación

Zitieren

APA

Calvo-Sánchez, H., Jara-Fernández, L., Encijo-Heredia, R., Villarino, I., Alvarado, R., Quiñones-Calvo, M., Gutiérrez, M. L., Miquel, J., Torralba, M., Catalá, M., Gómez, J., Albertos, S., Barquero-Pérez, Ó., Fernández-Rodríguez, C., & Larrubia, J. R. (2026). Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study. Liver International, 46(8). https://doi.org/10.1111/liv.70798

Vancouver

Calvo-Sánchez H, Jara-Fernández L, Encijo-Heredia R, Villarino I, Alvarado R, Quiñones-Calvo M, et al. Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study. Liver International. 2026;46(8). doi:10.1111/liv.70798

BibTeX
@article{CalvoSnchez2026,
  author = {Calvo-Sánchez, Henar and Jara-Fernández, Lorena and Encijo-Heredia, Raquel and Villarino, Irene and Alvarado, Rubén and Quiñones-Calvo, Marta and Gutiérrez, María-Luisa and Miquel, Joaquín and Torralba, Miguel and Catalá, Myriam and Gómez, José and Albertos, Sonia and Barquero-Pérez, Óscar and Fernández-Rodríguez, Conrado and Larrubia, Juan-Ramón},
  title = {Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR : A Multicentre Cohort Study},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {8},
  doi = {10.1111/liv.70798}
}
Kostenlos starten →